To Present on AVA6000 and AVA6103 at ESMO 2026
Avacta to present progression-free survival data on AVA6000 and FOCUS-01 trial design at ESMO 2026.
Select text to share a quote on X · sign in to keep highlights & notes in your AVCT notes
Avacta to Present Progression Free Survival Data on Faridoxorubicin (AVA6000) and the FOCUS-01 (AVA6103) Trial Design at the ESMO 2026 Congress
LONDON and PHILADELPHIA - October 14, 2026 - Avacta Therapeutics (AIM: AVCT, "the Company", "Avacta"), a life sciences company developing innovative, targeted oncology drugs, today announces the Company will present the most recent data analysis from the ongoing Phase 1a trial of Faridoxorubicin (AVA6000) and the design of the FOCUS-01 trial of FAP-Exd (AVA6103) in two poster presentations at the European Society for Medical Oncology (ESMO) 2026 Congress, to be held in Madrid from October 23-27, 2026.
A presentation on October 26, 2026 will include the progression-free survival (PFS) data in patients with salivary gland cancer (SGC) as well as FAPI-PET imaging data from this expansion cohort from the ongoing Phase 1a/1b trial of Faridoxorubicin (AVA6000) in patients with Fibroblast Activation Protein (FAP)-positive solid tumors
A second presentation featuring the design of the Phase 1 FOCUS-01 trial will include updated preclinical data on AVA6103.
Details of the presentations
A Phase 1a/1b trial of FAP-Dox (AVA6000), a Fibroblast Activation Protein (FAP)-released and tumor microenvironment (TME)-targeted doxorubicin peptide drug conjugate in patients with salivary gland cancers
Authors: Renata Ferrarotto, Robert Metcalf, Steph A. Pang, William D. Tap, et. al, Alan L. Ho
Poster number: 1549P
Time: Monday October 26, 12:00-12:45pm CET
| A phase I trial of FAP-Exd (AVA6103), a Fibroblast Activation Protein (FAP)-enabled pre | CISION® peptide-drug conjugate delivering sustained tumor microenvironment (TME) release of exatecan in patients with FAP-positive solid tumors |
Authors: Alexander I. Spira, Nehal J. Lakhani, Judy S. Wang, Muhammad R. Khawaja, Ruairidh Edwards, Karen Campbell, Curtis Rink, Christiana Nikolova, David Liebowitz
Poster number: 1134eTiP
Time: e-Poster TIP Session
| Avacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies through its proprietary pre | CISION® platform. pre | CISION® is a payload delivery system based on a tumor-specific protease (Fibroblast Activation Protein or FAP) that is designed to concentrate highly potent payloads in the tumor microenvironment while sparing normal tissues. Avacta's innovative pre | CISION® peptide drug conjugates (PDC) are a novel entry to the XDC drug class, leveraging the success of antibody drug conjugates with alternative methods of delivery beyond antibodies. |
| Our pre | CISION® PDCs leverage this tumor-specific release mechanism in a small molecule format to provide unique benefits over traditional antibody drug conjugates (ADC), releasing active payload in the tumor and reducing systemic exposure and toxicity which enables dosing to be optimized to deliver the best outcomes for patients. The lead clinical program is AVA6103, a Next Generation FAP-enabled controlled release pre | CISION® version of exatecan that delivers the payload directly in the tumor with limited peripheral blood exposure and is currently in clinical development as a treatment for tumor types sensitive to exatecan including cervical cancer, HR+ breast cancer, small cell lung cancer, gastric cancer, colorectal cancer and pancreatic cancer. |
About FAP-Exd (AVA6103)
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.